"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Although Morrhuate Sodium (morrhuate sodium injection) has been used as a sclerosing agent for the treatment of internal hemorrhoids, there is no substantial evidence that the drug is useful for this purpose.
Most patients with symptomatic primary varicosed veins should be treated initially with compression stockings. If this treatment is inadequate, surgery may be required. Sclerosing agents may be useful as a supplement to venous ligation to obliterate residual varicosed veins or in patients who have conditions which increase the risk of surgery. However, many clinicians consider if sclerotherapy is not effective it may decrease the potential success of later surgery, should this be required.
DOSAGE AND ADMINISTRATION
Morrhuate Sodium (morrhuate sodium injection) is administered only by INTRAVENOUS injection. Care must be taken to avoid extravasation. (see PRECAUTIONS.) Specialized references should be consulted for specific procedures and techniques of administration. When small veins are injected, or the injection solution is cold, or if solid matter has separated in the solution, the vial should be warmed by immersing in hot water. The solution should become clear on warming; only a clear solution should be used. Because the solution froths easily, a large bore needle should be used to fill the syringe. However, a small bore needle should be used for the injection.
To determine possible sensitivity to the drug, some clinicians recommend injection of 0.25 - 1 mL of 5% Morrhuate Sodium (morrhuate sodium injection) Injection into a varicosity 24 hours before administration of a large dose.
Dosage of Morrhuate Sodium (morrhuate sodium injection) depends on the size and degree of varicosity. The usual adult dose for obliteration of small or medium veins is 50- 100 mg (1-2 mL of the 5% injection). For large veins, 150- 250 (3-5 mL of the injection) is used. The drug may be given as multiple injections at one time or in single response. Following injection of Morrhuate Sodium (morrhuate sodium injection) , the vein promptly becomes hard and swollen for 2-4 inches, depending on the size and response of the vein. After 24 hours, the vein is hard and slightly tender to the touch (with little or no periphlebitis). The skin around the injection becomes light-bronze; this color usually disappears shortly. An aching sensation and feeling of stiffness usually occurs and lasts approximately 48 hours.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
|NDC 0517-3065-01|| |
30 mL Multiple Dose Vial, 50 mg/mL
Store at controlled room temperature 15°- 30° C (59°- 86° F). PROTECT FROM FREEZING.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Morrhuate Sodium Information
Report Problems to the Food and Drug Administration
Find out what women really need.